Abstract

Oligometastasis and oligo-recurrence: more than a mirage

Highlights

  • Cancer is widely regarded as a systemic disease

  • We provide a comprehensive introduction of evidence favoring the oligometastatic phenotype, we review the efficacy and safety of two methods to treat metastatic lesions [surgery and stereotactic body radiotherapy (SBRT)], and we discuss the manner in which oligometastasis can be differentiated from polymetastasis

  • Much evidence exists showing the efficacy of surgical resection of hepatic metastases from colorectal cancer, with 10-year overall survival (OS) rates of 17-28%, which is far better than those of patients treated with systemic therapy [12]

Read more

Summary

Introduction

Cancer is widely regarded as a systemic disease. Previously, cancer with metastasis has been considered stage IV, an end-stage disease, with the goal of palliative management. Within the population of cancer metastasis, emerging evidence has shown that a fraction of patients have an oligometastatic state, in which local therapy for metastatic lesions results in satisfactory survival comparable to non-metastatic disease. Much evidence exists showing the efficacy of surgical resection of hepatic metastases from colorectal cancer, with 10-year overall survival (OS) rates of 17-28%, which is far better than those of patients treated with systemic therapy [12]. The efficacy and tolerability of SBRT for liver metastasis has been confirmed by retrospective studies [23,24,25,26] showing local control rates around 80% or higher [27]. Takahashi et al conducted a retrospective analysis of 42 patients with lung oligo-recurrence who underwent SBRT, 2-year local control rate and 2-year OS rate were 87% and 65%. SBRT has emerged as a novel, promising and non-invasive

Conclusions
63. Suzuki H
Findings
66. Chamberlain MC
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call